Five-Year Follow Up of Thymoglobulin Versus ATGAM Induction in Adult Renal Transplantation

Background. One-year results of a randomized, double-blinded trial of Thymoglobulin versus Atgam for induction therapy in renal transplantation revealed that Thymoglobulin was associated with higher event-free survival (94% vs. 63%), less acute rejection (4% vs. 25%), and better graft survival. This article compares the safety and efficacy of Thymoglobulin versus Atgam induction through 5 years. Methods. Review and analysis of clinic records and electronic databases. Results. At 5 years, event-free survival (73% vs. 33%, P<0.001), graft survival (77% vs. 55%, P=0.047), and freedom from rejection (92% vs. 66%, P=0.007) were higher with Thymoglobulin versus Atgam. No additional cytomegalovirus (CMV) disease occurred after the first year with Thymoglobulin or Atgam (13% vs. 33%, P=0.056). There were two cases of posttransplant lymphoproliferative disorder (PTLD) with the Atgam arm and none with Thymoglobulin. Thymoglobulin was associated with profound lymphopenia at 2 years after transplantation. Conclusions. Thymoglobulin was associated with higher event-free survival, graft survival, and freedom from rejection without increased PTLD or CMV disease at 5 years compared with Atgam. The prolonged and profound lymphopenia may contribute to the long-term results associated with Thymoglobulin.

[1]  F. Delmonico,et al.  A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1 , 2003, Transplantation.

[2]  L. Genestier,et al.  Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins1 , 2003, Transplantation.

[3]  T. Howard,et al.  Short course induction immunosuppression with thymoglobulin for renal transplant recipients. , 2002, Transplantation.

[4]  J. Revillard,et al.  MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1 , 2001, Transplantation.

[5]  M. Schnitzler,et al.  A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. , 1999, Transplantation.

[6]  K. Lamborn,et al.  Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. , 1998, Transplantation.

[7]  F. Aubin,et al.  CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. , 1998, Transplantation.

[8]  M. Schnitzler,et al.  Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. , 1997, Transplantation.

[9]  H. Sprenger,et al.  Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. , 1997, Transplantation.

[10]  T. Howard,et al.  Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. , 1997, Journal of the American Society of Nephrology : JASN.